WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Rocket Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-10 10:25 am Purchase |
2024-12-31 | 13G | Rocket Pharmaceuticals, Inc. RCKT |
WELLINGTON MANAGEMENT CO LLP | 13,995,177 13.400% |
2,753,033 (+24.49%) |
Filing |
| 2024-11-08 10:52 am Purchase |
2024-09-30 | 13G | Rocket Pharmaceuticals, Inc. RCKT |
WELLINGTON MANAGEMENT CO LLP | 11,242,144 12.360% |
2,086,045 (+22.78%) |
Filing |
| 2024-04-05 09:47 am Purchase |
2024-03-29 | 13G | Rocket Pharmaceuticals, Inc. RCKT |
WELLINGTON MANAGEMENT CO LLP | 9,156,099 10.120% |
958,553 (+11.69%) |
Filing |
| 2024-02-08 10:17 am Purchase |
2023-12-29 | 13G | Rocket Pharmaceuticals, Inc. RCKT |
WELLINGTON MANAGEMENT CO LLP | 8,197,546 9.090% |
4,690,529 (+133.75%) |
Filing |
| 2023-02-06 2:56 pm Purchase |
2022-12-30 | 13G | Rocket Pharmaceuticals, Inc. RCKT |
WELLINGTON MANAGEMENT CO LLP | 3,507,017 4.450% |
16,138 (+0.46%) |
Filing |
| 2022-02-04 09:22 am Purchase |
2021-12-31 | 13G | Rocket Pharmaceuticals, Inc. RCKT |
WELLINGTON MANAGEMENT CO LLP | 3,490,879 5.420% |
3,490,879 (New Position) |
Filing |